FRM
AVDL

Fox Run Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Fox Run Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,436
Closed -$190K – 913
2025
Q2 		$190K Buy
+21,436
New +$188K 0.03% 758
2024
Q4 		– Sell
-25,981
Closed -$341K – 865
2024
Q3 		$341K Buy
+25,981
New +$396K 0.08% 496

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Fox Run Management's AVDL Position: Q3 2025 in Review

Fox Run Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2025, closing a stake of 21,436 shares — an estimated $190K sold.

Fox Run Management first reported a position in AVDL in Q3 2024 and held it in 2 quarters. The position peaked at $341K in Q3 2024. 188 funds tracked by Wall St. Rank hold AVDL as of Q3 2025.

  • Fox Run Management reported no remaining Avadel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Fox Run Management sold 21,436 Avadel Pharmaceuticals shares in Q3 2025, an estimated $190K.
  • Fox Run Management first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Fox Run Management's Avadel Pharmaceuticals position peaked at $341K in Q3 2024.
  • 188 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.